[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553658":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":32,"locations":38,"responsibleParty":56,"collaborators":58,"id":61,"slug":24,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":24,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":24,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":24,"overallStatus":41,"whyStopped":24,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Shanghai Juncell Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm B","EXPERIMENTAL","GC203 TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.",[13],"Biological: GC203 TIL(gene-edited TIL) or autologous TILs",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm A","GC101 TILs will be infused i.v. to patients with advanced solid tumors after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","GC203 TIL(gene-edited TIL) or autologous TILs","the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample",[15,9],null,[26,30],{"name":27,"affiliation":28,"role":29},"Qian Zhang","Eastern Hepatobiliary Surgery Hospital","PRINCIPAL_INVESTIGATOR",{"name":31,"affiliation":28,"role":29},"Wenlong Yu",[33],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"GC Clinical","CONTACT","086-18001759113","clinicaltrials@juncell.com",[39],{"facility":40,"status":41,"city":42,"state":24,"zip":24,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Third Affiliated Hospital of Naval Medical University","RECRUITING","Shanghai","China","CN",{"type":46,"coordinates":47},"Point",[48,49],121.45806,31.22222,{"lat":49,"lon":48},[52,54,55],{"name":53,"role":35,"phone":24,"phoneExt":24,"email":24},"Xiaoyun Tai",{"name":27,"role":29,"phone":24,"phoneExt":24,"email":24},{"name":31,"role":29,"phone":24,"phoneExt":24,"email":24},{"type":57,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[59],{"name":28,"class":60},"OTHER","100553658",false,"NCT06488950","A Study of TIL in Advanced Solid Tumors (DFGD)","A Study Study of Tumor Infiltrating Lymphocytes Injection (GC101\u002F203 TIL) in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* have one the tumor resection for TILs production and successfully produced；\n* Age: 18 years to 75years;\n* Histologically diagnosed as solid tumors;\n* Expected life-span more than 3 months;\n* ECOG score 0-1;\n* Test subjects have failed standard treatment regimens, and be willing to receive TIL therapy;\n* At least 1 evaluable tumor lesion;\n\nExclusion Criteria:\n\n* with other malignant tumors, except for the malignancies that have been cured, have been inactive for ≥5 years prior to study inclusion and have a very low risk of recurrence; Non-melanoma skin cancer or malignant lentigo with adequate treatment and no evidence of disease recurrence; Carcinoma in situ with adequate treatment and no evidence of disease recurrence;\n* Need glucocorticoid treatment, and daily dose of Prednisone greater than 10mg(or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment;\n* Breathe indoor air in a quiet state, and the oxygen saturation of finger pulse is \\\u003C 95%;\n* Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and\u002For anti-HCV positive), syphilis infection or Treponema pallidum antibody positive;\n* Significant cardiovascular anomalies","ALL","18 Years","75 Years",{"count":71,"type":72},30,"ESTIMATED","INTERVENTIONAL",[75],"EARLY_PHASE1","This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.",[78,79,80,81],"Advanced Solid Tumor","Tumor Infiltrating Lymphocytes","Treatment Side Effects","Effects of Immunotherapy","2025-12-08",{"date":84,"type":85},"2025-12-16","ACTUAL",{"date":87,"type":85},"2023-04-01",{"date":89,"type":72},"2027-06-30",{"name":5,"class":6},1]